National Atrial Fibrillation Awareness Month

United States

About

National Atrial Fibrillation Awareness Month is observed throughout September to raise awareness of atrial fibrillation, often called AFib—a common heart rhythm condition in which the heart beats irregularly or rapidly. The observance helps people better understand AFib, recognize possible warning signs such as heart palpitations, shortness of breath, fatigue, or dizziness, and appreciate the importance of discussing concerning symptoms with a healthcare professional.

Throughout the month, individuals and communities are encouraged to learn about heart health, risk factors, diagnosis, and treatment options. National Atrial Fibrillation Awareness Month also highlights the value of regular medical care and healthy lifestyle choices, while reminding those living with AFib that support, education, and proper management can help them protect their well-being.

History

National Atrial Fibrillation Awareness Month is observed throughout September to promote public understanding of atrial fibrillation, commonly called AFib or AF. The observance emerged from growing concern about a widespread heart-rhythm disorder that can cause an irregular and often rapid heartbeat. Although AFib had long been recognized by physicians, advances in electrocardiography and cardiac care made it easier to identify, monitor, and treat. Over time, medical organizations, hospitals, patient advocates, and public-health groups increasingly emphasized the importance of recognizing the condition early.

The history of the awareness month reflects broader progress in cardiovascular medicine. Earlier public discussions of heart disease often centered on heart attacks and high blood pressure, while abnormal heart rhythms received less general attention. As researchers established the strong connection between AFib and ischemic stroke, awareness efforts began stressing that the condition is more than an uncomfortable or inconvenient heartbeat. Educational campaigns have helped explain how age, hypertension, valvular disease, diabetes, sleep apnea, and other cardiovascular factors can contribute to AFib, while also encouraging people to discuss irregular pulse readings or symptoms with qualified health professionals.

Over the years, National Atrial Fibrillation Awareness Month has evolved from a primarily medical education effort into a broader public-health observance. Information shared during September commonly addresses symptoms such as palpitations, fatigue, shortness of breath, dizziness, and reduced exercise tolerance, while noting that some people experience no obvious symptoms. Campaigns also highlight the importance of individualized treatment, which may include medications, procedures, rhythm or rate management, and measures to reduce stroke risk. The emphasis is generally on informed conversations with clinicians rather than self-diagnosis or a single treatment approach.

Culturally, the observance helps make an often-invisible health problem more understandable to patients, families, and communities. It gives advocacy groups and healthcare providers an opportunity to challenge misconceptions—for example, the idea that an irregular heartbeat is always harmless or that it affects only older adults. By connecting personal stories with medical education, September outreach encourages people to take cardiovascular symptoms seriously and to learn about prevention, monitoring, and treatment. In this way, National Atrial Fibrillation Awareness Month contributes to the larger history of heart-health advocacy by turning specialized knowledge about cardiac rhythm into practical public awareness.

Timeline

1909
British cardiologist Thomas Lewis used electrocardiography to describe and establish atrial fibrillation as a distinct cardiac rhythm disorder, then commonly called auricular fibrillation.
1998
Michel Haïssaguerre and colleagues reported that ectopic beats originating in the pulmonary veins could initiate atrial fibrillation, a finding that helped establish pulmonary-vein catheter ablation as a treatment approach.
2002
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial was published, finding no survival advantage for rhythm-control therapy over rate control in many patients with atrial fibrillation.
2010
The U.S. Food and Drug Administration approved dabigatran etexilate to reduce stroke and systemic embolism risk in patients with nonvalvular atrial fibrillation, introducing the first widely used direct oral anticoagulant for this indication.

Upcoming dates

Sources

Same day

Related